Safety, Tolerability, and Pharmacokinetic Evaluation of Single and Multiple Doses of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib in Healthy Japanese and White Adults

Brensocatib, an investigational first‐in‐class, small‐molecule, orally bioavailable, selective, and reversible dipeptidyl peptidase 1 inhibitor that blocks activation of neutrophil serine proteases, is currently under clinical development for the treatment of bronchiectasis and other chronic inflamm...

Descripción completa

Detalles Bibliográficos
Autores principales: Usansky, Helen, Yoon, Esther, Teper, Ariel, Zou, Jun, Fernandez, Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322451/
https://www.ncbi.nlm.nih.gov/pubmed/35411669
http://dx.doi.org/10.1002/cpdd.1094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322451/
https://www.ncbi.nlm.nih.gov/pubmed/35411669
http://dx.doi.org/10.1002/cpdd.1094

Ejemplares similares